<DOC>
	<DOCNO>NCT01285089</DOCNO>
	<brief_summary>This study conduct Europe . The aim prospective , observational study describe different clinical practice detail haemostatic management activate recombinant human factor VII ( NovoSeven® ) patient acquire haemophilia France . The secondary aim ass primary haemostasis disorder associate coagulation disorder , available .</brief_summary>
	<brief_title>Observational Study Use NovoSeven® Haemostatic Treatment Bleeding Episodes Patients With Acquired Haemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Diagnosed acquire haemophilia Treated activate recombinant human factor VII first line treatment Treated activate recombinant human factor VII January 2011 Patients first diagnosis january 2010 relapse january 2011 Known hypersensitivity NovoSeven® , mouse , hamster bovine protein</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>